Literature DB >> 18287387

Cancer statistics, 2008.

Ahmedin Jemal1, Rebecca Siegel, Elizabeth Ward, Yongping Hao, Jiaquan Xu, Taylor Murray, Michael J Thun.   

Abstract

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,437,180 new cancer cases and 565,650 deaths from cancer are projected to occur in the United States in 2008. Notable trends in cancer incidence and mortality include stabilization of incidence rates for all cancer sites combined in men from 1995 through 2004 and in women from 1999 through 2004 and a continued decrease in the cancer death rate since 1990 in men and since 1991 in women. Overall cancer death rates in 2004 compared with 1990 in men and 1991 in women decreased by 18.4% and 10.5%, respectively, resulting in the avoidance of over a half million deaths from cancer during this time interval. This report also examines cancer incidence, mortality, and survival by site, sex, race/ethnicity, education, geographic area, and calendar year, as well as the proportionate contribution of selected sites to the overall trends. Although much progress has been made in reducing mortality rates, stabilizing incidence rates, and improving survival, cancer still accounts for more deaths than heart disease in persons under age 85 years. Further progress can be accelerated by supporting new discoveries and by applying existing cancer control knowledge across all segments of the population.

Entities:  

Mesh:

Year:  2008        PMID: 18287387     DOI: 10.3322/CA.2007.0010

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  2000 in total

1.  Sunlight exposure and cutaneous human papillomavirus seroreactivity in basal cell and squamous cell carcinomas of the skin.

Authors:  Michelle R Iannacone; Wei Wang; Heather G Stockwell; Kathleen O'Rourke; Anna R Giuliano; Vernon K Sondak; Jane L Messina; Richard G Roetzheim; Basil S Cherpelis; Neil A Fenske; Kristina M Michael; Tim Waterboer; Michael Pawlita; Dana E Rollison
Journal:  J Infect Dis       Date:  2012-06-01       Impact factor: 5.226

2.  Demethylating agent 5-aza-2-deoxycytidine enhances susceptibility of breast cancer cells to anticancer agents.

Authors:  Sameer Mirza; Gayatri Sharma; Pranav Pandya; Ranju Ralhan
Journal:  Mol Cell Biochem       Date:  2010-05-09       Impact factor: 3.396

3.  IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis.

Authors:  Yanxia Ning; Rebecca B Riggins; Jennifer E Mulla; Haniee Chung; Alan Zwart; Robert Clarke
Journal:  Mol Cancer Ther       Date:  2010-05       Impact factor: 6.261

Review 4.  Radiomics in precision medicine for lung cancer.

Authors:  Julie Constanzo; Lise Wei; Huan-Hsin Tseng; Issam El Naqa
Journal:  Transl Lung Cancer Res       Date:  2017-12

5.  Lysocardiolipin acyltransferase regulates NSCLC cell proliferation and migration by modulating mitochondrial dynamics.

Authors:  Long Shuang Huang; Sainath R Kotha; Sreedevi Avasarala; Michelle VanScoyk; Robert A Winn; Arjun Pennathur; Puttaraju S Yashaswini; Mounica Bandela; Ravi Salgia; Yulia Y Tyurina; Valerian E Kagan; Xiangdong Zhu; Sekhar P Reddy; Tara Sudhadevi; Prasanth-Kumar Punathil-Kannan; Anantha Harijith; Ramaswamy Ramchandran; Rama Kamesh Bikkavilli; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2020-07-30       Impact factor: 5.157

6.  Clusterin is a gene-specific target of microRNA-21 in head and neck squamous cell carcinoma.

Authors:  Wojciech Mydlarz; Mamoru Uemura; Sun Ahn; Patrick Hennessey; Steven Chang; Semra Demokan; Wenyue Sun; Chunbo Shao; Justin Bishop; Julie Krosting; Elizabeth Mambo; William Westra; Patrick Ha; David Sidransky; Joseph Califano
Journal:  Clin Cancer Res       Date:  2013-12-10       Impact factor: 12.531

7.  shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.

Authors:  Peng Jin; Jinliang Xie; Xiangrong Zhu; Cheng Zhou; Xiang Ding; Luoyan Yang
Journal:  Int Urol Nephrol       Date:  2013-12-11       Impact factor: 2.370

8.  A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy.

Authors:  María Elena Martínez; John A Baron; David A Lieberman; Arthur Schatzkin; Elaine Lanza; Sidney J Winawer; Ann G Zauber; Ruiyun Jiang; Dennis J Ahnen; John H Bond; Timothy R Church; Douglas J Robertson; Stephanie A Smith-Warner; Elizabeth T Jacobs; David S Alberts; E Robert Greenberg
Journal:  Gastroenterology       Date:  2008-12-09       Impact factor: 22.682

9.  p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.

Authors:  Srirupa Roy; Mallikarjuna Gu; Kumaraguruparan Ramasamy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert A Sclafani; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

10.  Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.

Authors:  Imtiyaz Murtaza; Mohammad Saleem; Vaqar Mustafa Adhami; Bilal Bin Hafeez; Hasan Mukhtar
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.